Bios funds report 4.48% Lantern Pharma (NASDAQ: LTRN) stake

Rhea-AI Filing Summary

Lantern Pharma Inc. (LTRN) received an updated ownership report from a group of Bios-related investment entities and principals via Amendment No. 7 to their Schedule 13D. The group reports beneficial ownership of 571,305 shares of Lantern Pharma common stock, representing 4.48% of the outstanding shares.

These shares are held across several funds, including Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT, with entities such as Bios Advisors GP, Bios Capital Management, Bios Equity Partners and Bios Equity Partners II, and individuals Aaron G.L. Fletcher and Leslie W. Kreis deemed to share voting and dispositive power.

The percentages are calculated using 12,758,872 Lantern Pharma shares outstanding, based on 11,304,697 shares from a Form 10-K and 1,454,175 additional shares from a Form 8-K. The filing states that, aside from any exceptions described, only the reporting persons have rights to dividends or sale proceeds for the reported shares.

Key Figures

Group beneficial ownership: 571,305 shares Group ownership percentage: 4.48% of class Shares outstanding base: 12,758,872 shares +4 more

7 metrics

Group beneficial ownership 571,305 shares Lantern Pharma common stock reported by Bios-related group

Group ownership percentage 4.48% of class Based on Lantern Pharma shares outstanding

Shares outstanding base 12,758,872 shares 11,304,697 from Form 10-K plus 1,454,175 from Form 8-K

Bios Equity Partners stake 266,621 shares (2.09%) Lantern Pharma common stock held via Bios Fund I entities

Bios Equity Partners II stake 304,684 shares (2.39%) Lantern Pharma common stock held via Bios Fund II entities

Bios Fund I holding 151,759 shares Directly held by Bios Fund I, LP

Bios Fund II QP holding 211,566 shares Directly held by Bios Fund II QP, LP

Key Terms

beneficially owned, shared voting power, shared dispositive power, Schedule 13D, +1 more

5 terms

beneficially owned financial

"11Aggregate amount beneficially owned by each reporting person 571,305.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power 0.00 8 | Shared Voting Power 571,305.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"9 | Sole Dispositive Power 0.00 10 | Shared Dispositive Power 571,305.00"

Schedule 13D regulatory

"This Amendment No. 7 hereby amends and supplements the statement on originally filed with the Securities and Exchange Commission"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Percent of class represented financial

"13Percent of class represented by amount in Row (11) 4.48 %"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

Lantern Pharma Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

51654W101

(CUSIP Number)

Bios Equity Partners, LP
1751 River Run, Suite 400
Fort Worth, TX, 76107
817-984-9197

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/15/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS ADVISORS GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 571,305.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 571,305.00

11

Aggregate amount beneficially owned by each reporting person

571,305.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.48 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

AARON G.L. FLETCHER

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 571,305.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 571,305.00

11

Aggregate amount beneficially owned by each reporting person

571,305.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.48 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

CAVU MANAGEMENT, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 571,305.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 571,305.00

11

Aggregate amount beneficially owned by each reporting person

571,305.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.48 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

CAVU ADVISORS, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 571,305.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 571,305.00

11

Aggregate amount beneficially owned by each reporting person

571,305.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.48 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

LESLIE W. KREIS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF, OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 571,305.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 571,305.00

11

Aggregate amount beneficially owned by each reporting person

571,305.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.48 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS EQUITY PARTNERS, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 266,621.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 266,621.00

11

Aggregate amount beneficially owned by each reporting person

266,621.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.09 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP (Bios Equity I) is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS EQUITY PARTNERS II, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 304,684.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 304,684.00

11

Aggregate amount beneficially owned by each reporting person

304,684.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.39 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 64,794 Shares directly held by Bios Fund II, (ii) 211,566 Shares directly held by Bios Fund II QP and (iii) 28,324 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP (Bios Equity II) is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS CAPITAL MANAGEMENT, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 571,305.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 571,305.00

11

Aggregate amount beneficially owned by each reporting person

571,305.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.48 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS FUND II NT, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 28,324.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 28,324.00

11

Aggregate amount beneficially owned by each reporting person

28,324.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.22 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS FUND II QP, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 211,566.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 211,566.00

11

Aggregate amount beneficially owned by each reporting person

211,566.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.66 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS FUND II, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 64,794.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 64,794.00

11

Aggregate amount beneficially owned by each reporting person

64,794.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.51 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BP DIRECTORS, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 26,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 26,093.00

11

Aggregate amount beneficially owned by each reporting person

26,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

BIOS FUND I QP, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 88,769.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 88,769.00

11

Aggregate amount beneficially owned by each reporting person

88,769.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

CUSIP Number(s): 51654W101

1

Name of reporting person

Bios Fund I, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 151,759.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 151,759.00

11

Aggregate amount beneficially owned by each reporting person

151,759.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.19 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Lantern Pharma Inc.
(c)	Address of Issuer's Principal Executive Offices: 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS, TEXAS , 75201.
Item 1 Comment: This Amendment No. 7 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statements on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), March 1, 2024 ("Amendment No. 3"), June 12, 2025 ("Amendment No. 4"), February 23, 2026 ("Amendment No. 5"), April 16, 2026 ("Amendment 6") and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, and Amendment No. 6, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer").
Item 5.	Interest in Securities of the Issuer
(a)	The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.
(b)	The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.
(d)	Except as described in this Amendment No. 7, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D.
(e)	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOS ADVISORS GP, LLC

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

AARON G.L. FLETCHER

Signature:	/s/ John Fucci
Name/Title:	John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher
Date:	05/15/2026

CAVU MANAGEMENT, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

CAVU ADVISORS, LLC

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

LESLIE W. KREIS

Signature:	/s/ John Fucci
Name/Title:	John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr.
Date:	05/15/2026

BIOS EQUITY PARTNERS, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BIOS EQUITY PARTNERS II, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BIOS CAPITAL MANAGEMENT, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BIOS FUND II NT, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BIOS FUND II QP, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BIOS FUND II, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BP DIRECTORS, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

BIOS FUND I QP, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

Bios Fund I, LP

Signature:	/s/ John Fucci
Name/Title:	John Fucci/Attorney-in-Fact
Date:	05/15/2026

Comments accompanying signature:

BIOS FUND II, LP By: Bios Equity Partners II, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS FUND II QP, LP By: Bios Equity Partners II, LP, itsgeneral partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP,LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II NT, LPBy: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its generalpartner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorneyin-Fact BIOS INCYSUS CO-INVEST I, LP By: Bios Equity Partners II, LP, its general partnerBy: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its generalpartner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III, LP By: Bios EquityPartners III, LP, its general partner By: Bios Capital Management, LP, its general partner By:Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOSFUND III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS FUND III NT, LP By: Bios Equity Partners III, LP, itsgeneral partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP,LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS CLINICALOPPORTUNITY FUND, LP By: Bios Equity COF, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner BPDIRECTORS, LP By: Bios Equity Partners, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS II, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in Fact BIOS EQUITY PARTNERS III, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY COF, LP By: Bios Capital Management, LP, itsgeneral partner By: Bios Advisors GP, LLC, its general partner CAVU MANAGEMENT, LP By:Cavu Advisors, LLC, its general partner By: /s/ John Fucci Attorney-in-Fact BIOS CAPITALMANAGEMENT, LP By: Bios Advisors GP, LLC its general partner By: /s/ John Fucci Attorney in-Fact

FAQ

What ownership stake in Lantern Pharma (LTRN) do the Bios entities report?

The Bios-related reporting group reports beneficial ownership of 571,305 Lantern Pharma shares, equal to 4.48% of the common stock. These shares are held across multiple Bios funds, with shared voting and dispositive power among affiliated entities and principals.

How many Lantern Pharma (LTRN) shares are used to calculate the 4.48% ownership?

The 4.48% figure is based on 12,758,872 Lantern Pharma shares outstanding. This total includes 11,304,697 shares from a Form 10-K and 1,454,175 shares from a Form 8-K referenced in the ownership disclosure.

Which funds hold Lantern Pharma (LTRN) shares for the Bios reporting group?

The filing attributes shares to Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, and Bios Fund II NT. These entities collectively hold the 571,305 shares reported with shared voting and dispositive power.

What individual roles do Aaron G.L. Fletcher and Leslie W. Kreis have in the LTRN holding?

Aaron G.L. Fletcher and Leslie W. Kreis are reporting persons who may be deemed to share voting and dispositive power over the Lantern Pharma shares. Each participates through control of general partner entities overseeing the various Bios funds that directly hold the stock.

What is Amendment No. 7 to the Lantern Pharma (LTRN) Schedule 13D?

Amendment No. 7 updates a previously filed Schedule 13D for Lantern Pharma common stock. It restates current beneficial ownership, voting and dispositive power details for the Bios-related reporting group, building on prior amendments originally filed starting in June 2020.

How much of Lantern Pharma does Bios Equity Partners and Bios Equity Partners II each hold?

Bios Equity Partners, LP reports 266,621 Lantern Pharma shares, or 2.09% of the class. Bios Equity Partners II, LP reports 304,684 shares, or 2.39%. Each percentage is calculated against the same 12,758,872-share outstanding base.